A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
Study is to evaluate if ART-123 given to patients who have severe sepsis complicated by at least one organ dysfunction and coagulopathy can decrease mortality.
Inclusion Criteria:
Exclusion Criteria:
São José do Rio Preto, São Paulo, Brazil
Plovdiv, Bulgaria
Sofia, Bulgaria
Zagreb, Croatia
Hradec Králové, Czechia
Prague, Czechia
Prague, Czechia
Helsinki, Finland
Tampere, Finland
New Delhi, National Capital Territory of Delhi, India
Pune, Pune, Maharashtra 411043, India
Krasnodar, Russia